S&CO Inc. Has $1.45 Million Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

S&CO Inc. decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 17.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,000 shares of the company's stock after selling 25,000 shares during the quarter. S&CO Inc.'s holdings in Elanco Animal Health were worth $1,453,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ELAN. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health during the third quarter worth approximately $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health during the third quarter worth approximately $35,000. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock worth $49,000 after buying an additional 2,044 shares in the last quarter. Venturi Wealth Management LLC grew its position in shares of Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock worth $50,000 after buying an additional 1,601 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after buying an additional 2,059 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.57% of the stock is currently owned by company insiders.

Remove Ads

Elanco Animal Health Stock Performance

ELAN stock traded up $0.16 during mid-day trading on Friday, reaching $10.47. The company had a trading volume of 4,680,857 shares, compared to its average volume of 4,663,851. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $5.18 billion, a P/E ratio of 26.16, a P/E/G ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a one year low of $10.03 and a one year high of $18.80. The stock's 50-day simple moving average is $11.49 and its two-hundred day simple moving average is $12.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.08 earnings per share. Research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of recent analyst reports. Morgan Stanley decreased their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Barclays reduced their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus reduced their price objective on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. Leerink Partnrs upgraded Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Finally, UBS Group reduced their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.